Schedule 13G ownership disclosure

Protalix BioTherapeutics, Inc.

Security class unavailable · CUSIP: 74365A101

Event date: 2017-06-30

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
4,845,682
Percent of class
3.7400%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001623632-17-001520
Form type
SC 13G/A
Filer
FEDERATED HERMES, INC.
CIK
CIK 1056288
Filed
Jul 10, 2017
Reporting period
Jun 30, 2017
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub